
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics Inc demonstrated strong financial performance, with management reporting that its Integrity product achieved sequential revenue growth and is projected to exceed 100% growth in 2025 compared to 2024. The company’s regenerative solutions segment experienced notable growth of 41% for the quarter, primarily attributed to the Integrity patch, indicating robust demand in its product line. Additionally, international revenue from osteoarthritis pain rose by 21% year-over-year, reflecting the company's successful expansion and strategic positioning in the orthopedic market.
Bears say
Anika Therapeutics reported a decline in revenue for multiple periods, with figures of $27.8 million and $28.2 million reflecting decreases of 5.9% and 8.2%, respectively, on a constant currency basis, indicating ongoing challenges in maintaining sales momentum. The company's gross margin fell to 56%, below the estimated 58%, due in part to persistent production yield issues impacting profitability. Additionally, international revenue from osteoarthritis pain therapies decreased by 10%, attributed to order timing and similar production challenges, reinforcing concerns regarding the company's operational efficiency and financial stability.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares